Sensei Biotherapeutics, Inc. - 8-K Filing
Sensei Biotherapeutics announced its annual meeting on June 10, 2026 to seek shareholder approval for the conversion of Series B Non-Voting Convertible Preferred Stock into shares of common stock. This conversion will result in over 24 million new common shares and a change of control under Nasdaq rules. The company provided unaudited pro forma financials showing $170.2M net loss for Q1 2026, with no revenue reported. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $SNSE